How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure

2006 American Heart Journal 270 citations

Abstract

B-type natriuretic peptide (BNP) is valuable in diagnosing heart failure (HF), but its utility in obese patients is unknown. Studies have suggested a cut-point of BNP > or = 100 pg/mL for the diagnosis of HF; however, there is an inverse relation between BNP levels and body mass index. We evaluated differential cut-points for BNP in diagnosing acute HF across body mass index levels to determine whether alternative cut-points can improve diagnosis. The Breathing Not Properly Multinational Study was a 7-center, prospective study of 1586 patients who presented to the Emergency Department with acute dyspnea. B-type natriuretic peptide was measured on arrival. Height and weight data were available for 1368 participants. The clinical diagnosis of HF was adjudicated by 2 independent cardiologists who were blinded to BNP results. Heart failure was the final diagnosis in 46.1%. Mean BNP levels (pg/mL) in lean, overweight/obese, and severely/morbidly obese patients were 643, 462, and 247 for patients with acute HF, and 52, 35, and 25 in those without HF, respectively (P < .05 for all comparisons except 35 vs 25). B-type natriuretic peptide cut-points to maintain 90% sensitivity for a HF diagnosis were 170 pg/mL for lean subjects, 110 pg/mL for overweight/obese subjects, and 54 pg/mL in severely/morbidly obese patients. Body mass index influences the selection of cut-points for BNP in diagnosing acute HF. A lower cut-point (BNP > or = 54 pg/mL) should be used in severely obese patients to preserve sensitivity. A higher cut-point in lean patients (BNP > or = 170 pg/mL) could be used to increase specificity.

Keywords

MedicineNatriuretic peptideHeart failureObesityInternal medicineCardiologyEndocrinology

MeSH Terms

Acute DiseaseAgedBody Mass IndexCohort StudiesDyspneaFemaleHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicNatriuretic PeptideBrainObesitySensitivity and SpecificitySeverity of Illness IndexSingle-Blind Method

Affiliated Institutions

Related Publications

Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)

Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global ...

2014 European Journal of Heart Failure 167 citations

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone sys...

2013 European Journal of Heart Failure 439 citations

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...

2019 European Journal of Heart Failure 430 citations

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Abstract In this document, we propose a universal definition of heart failure (HF) as a clinical syndrome with symptoms and/or signs caused by a structural and/or functional car...

2021 European Journal of Heart Failure 1374 citations

Publication Info

Year
2006
Type
article
Volume
151
Issue
5
Pages
999-1005
Citations
270
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

270
OpenAlex
12
Influential
223
CrossRef

Cite This

Lori B. Daniels, Paul Clopton, Vikas Bhalla et al. (2006). How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. American Heart Journal , 151 (5) , 999-1005. https://doi.org/10.1016/j.ahj.2005.10.011

Identifiers

DOI
10.1016/j.ahj.2005.10.011
PMID
16644321

Data Quality

Data completeness: 81%